FIFrancesco Iemolo

Francesco Iemolo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesco Iemolo has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    De novo mutation in a male patient with Fabry disease: a case report

    by Francesco Iemolo, Federica Pizzo, Giuseppe Albeggiani, Carmela Zizzo, Paolo Colomba, Simone Scalia, Caterina Bartolotta, Giovanni Duro

    Fabry disease is an X-linked inherited metabolic condition where the deficit of the α-galactosidase A enzyme, encoded by the GLA gene, leads to glycosphingolipid storage, mainly globotriaosylceramide. To date, more than 600 mutations have been identified in human GLA gene that are responsible for FD, including missense and nonsense mutations, small and large deletions. Such mutations are usually inherited, and cases of de novo onset occur rarely.


  • Identification of a novel mutation in the alpha-galactosidase A gene in patients with Fabry disease

    by Paolo Colomba, Antonia Nucera, Carmela Zizzo, Giuseppe Albeggiani, Daniele Francofonte, Francesco Iemolo, Antonino Tuttolomondo, Antonio Pinto, Giovanni Duro


  • Open Access

    A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report

    by Antonio Pisani, Massimo Imbriaco, Carmela Zizzo, Giuseppe Albeggiani, Paolo Colomba, Riccardo Alessandro, Francesco Iemolo, Giovanni Duro

    Background: Fabry disease (FD) is a hereditary metabolic disorder caused by the partial or total inactivation of a lysosomal hydrolase, the enzyme α-galactosidase A (GLA). This inactivation is responsible for the storage of undegraded glycosphingolipids in the lysosomes with subsequent cellular and microvascular dysfunction. The incidence of disease is estimated at 1:40,000 in the general population, although neonatal screening initiatives have found an unexpectedly high prevalence of genetic alterations, up to 1:3,100, in newborns in Italy, and have identified a surprisingly high frequency of newborn males with genetic alterations (about 1:1,500) in Taiwan. Case presentation: We describe the case of a 40-year-old female patient who presented with transient ischemic attack (TIA), discomfort in her hands, intolerance to cold and heat, severe angina and palpitations, chronic kidney disease. Clinical, biochemical and molecular studies were performed. Conclusions: Reported symptoms, peculiar findings in a renal biopsy – the evidence of occasional lamellar inclusions in podocytes and mesangial cells – and left ventricular (LV) hypertrophy, which are considered to be specific features of FD, as well as molecular evaluations, suggested the diagnosis of a classical form of FD. We detected four mutations in the GLA gene of the patient: -10C>T (g.1170C>T), c.370-77_-81del (g.7188-7192del5), c.640-16A>G (g.10115A>G), c.1000-22C>T (g.10956C>T). These mutations, located in promoter and intronic regulatory regions, have been observed in several patients with manifestations of FD. In our patient clinical picture showed a multisystemic involvement with early onset of symptoms, thus suggesting that these intronic mutations can be found even in patients with classical form of FD.


  • Open Access

    Genetic screening of Fabry patients with EcoTILLING and HRM technology

    by Caterina Bono, Domenico Nuzzo, Giuseppe Albeggiani, Carmela Zizzo, Daniele Francofonte, Francesco Iemolo, Enzo Sanzaro, Giovanni Duro

    Anderson-Fabry disease (FD) is caused by a deficit of the α-galactosidase A enzyme which leads to the accumulation of complex sphingolipids, especially globotriaosylceramide (Gb3), in all the cells of the body, causing the onset of a multi-systemic disease with poor prognosis in adulthood. In this article, we describe two alternative methods for screening the GLA gene which codes for the α-galactosidase A enzyme in subjects with probable FD in order to test analysis strategies which include or rely on initial pre-screening.


  • Open Access

    Pathophysiology of vascular dementia

    by Francesco Iemolo, Giovanni Duro, Claudia Rizzo, Laura Castiglia, Vladimir Hachinski, Calogero Caruso

    The concept of Vascular Dementia (VaD) has been recognized for over a century, but its definition and diagnostic criteria remain unclear. Conventional definitions identify the patients too late, miss subjects with cognitive impairment short of dementia, and emphasize consequences rather than causes, the true bases for treatment and prevention. We should throw out current diagnostic categories and describe cognitive impairment clinically and according to commonly agreed instruments that document the demographic data in a standardized manner and undertake a systematic effort to identify the underlying aetiology in each case. Increased effort should be targeted towards the concept of and criteria for Vascular Cognitive Impairment and Post-Stroke Dementia as well as for genetic factors involved, especially as these categories hold promise for early prevention and treatment.